Insurance Updates – May 2025

New York Medicaid Enforces Strict NDC Requirements for HCPCS J-Code Claims 

New York Medicaid has implemented stringent National Drug Code (NDC) reporting requirements for claims involving HCPCS J-codes, a critical update for healthcare providers billing physician-administered drugs. As outlined in the New York State Medicaid Update – July 2022, claims lacking a correct NDC or featuring a mismatched NDC will be denied, particularly for institutional claims with a UD modifier indicating drugs purchased at the 340B price. This policy, effective for all relevant claims, aims to enhance accuracy and compliance in Medicaid billing. 

Why NDC Compliance Matters 

The NDC, an 11-digit identifier unique to each drug product, ensures precise tracking of medications by specifying the manufacturer, product, and package size. For New York Medicaid, accurate NDC reporting is essential to validate claims, prevent fraud, and secure federal rebates under the Medicaid Drug Rebate Program. The UD modifier, used for 340B drugs, further complicates billing, as these claims require the NDC, actual acquisition cost, and units administered to avoid duplicate discounts. 

The New York State Department of Health has identified common J-code/NDC mismatches leading to claim denials, including: 

• Incorrect drug: Billing an NDC for a different medication than the J-code specifies. 

• Incorrect route of administration: Using an NDC for a drug with a mismatched delivery method (e.g., oral vs. injectable). 

• Incorrect package size: Reporting an NDC for a package size not administered, skewing reimbursement calculations. 

These errors disrupt revenue cycles and delay patient care, making compliance a priority for providers. 

Steps to Avoid Claim Denials 

To ensure seamless reimbursement, providers must align J-codes with the corresponding NDC using the CMS NDC-to-HCPCS Crosswalk and ASP Pricing Files, updated quarterly. Key actions include: 

• Verify NDC accuracy: Cross-reference the NDC on the drug vial or package with the J-code using the CMS crosswalk. Ensure the 5-4-2 NDC format (e.g., 12345-1234-12) is correctly entered without hyphens. 

• Implement regular reviews: Establish a process to check crosswalk updates, as new drugs or package sizes may alter mappings. 

• Train billing staff: Educate teams on NDC requirements, especially for 340B drugs requiring the UD modifier, to reduce errors. 

• Use technology: Leverage billing software that integrates CMS crosswalks to flag mismatches before submission.